Nervio

What Nervio does

Nervio Ltd. is an Israel-based medical technology company founded in 2020 that develops AIM™, an AI-powered intraoperative neuromonitoring (IONM) software platform. AIM™ ingests raw neurophysiological signals from surgical procedures and converts them into real-time alerts and recommendations that flag critical changes during spine, neurosurgical, and ENT operations. The system is built on proprietary machine learning algorithms trained and validated on more than 1,000 real surgeries, and is positioned as a vigilant adjunct to existing IONM platforms rather than a replacement for supervising neurophysiologists. Its primary functional value is enabling a single neurophysiologist to oversee multiple cases simultaneously, addressing a documented shortage of qualified experts that currently leaves approximately 80% of neurosurgeries unmonitored in the US.

The company targets two principal customer segments: hospitals and surgical centers performing neuromonitored procedures, and IONM service providers (the specialized companies that supply technologists and supervising neurophysiologists to those facilities). The commercial GTM motion is contingent on US FDA clearance, which is being pursued via an accepted submission plan and a clinical trial at the Global Neurosciences Institute. Until clearance is obtained, AIM™ is pre-commercial: products are not cleared for sale in the US, no pricing is publicly disclosed, and the intended revenue model is a recurring software subscription. The company has a wholly-owned US subsidiary, Nervio Inc., headquartered in Nashville, Tennessee, led by Dr. Richard Vogel, a past president of ASNM, and has secured strategic pre-commercial partnerships with dominant US IONM service providers Bromedicon and Medsurant Health. Investors include eHealth Ventures, MediPress Ventures, Spes Medica, Orgil Medical, and Mor Research Applications, with approximately $2.5M in total disclosed seed funding.

Name

Nervio

Legal name

Nervio Ltd.

Website

https://nervio.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Nervio develops AIM™, an AI-powered intraoperative neuromonitoring (IONM) software that converts surgical neurophysiological data into real-time alerts. It is pre-commercial and pre-FDA, targeting US hospitals, surgical centers, and IONM service providers facing a shortage of neurophysiologists.

Ownership category

akta.pro rank

Product category

Intraoperative Neuromonitoring Software

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Intraoperative neuromonitoring
• AI surgical monitoring
• Neuromonitoring software
• Surgical decision support
• Neurosurgery AI platform

Headquarters

HQ city

Misgav

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. AI-IONM Software Platform: Pre-commercialization stage. AIM™ is positioned as a software platform that adds an expert neurophysiologist capability to surgical teams. Revenue model not yet disclosed publicly.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Nervio develops AIM™, an AI-powered intraoperative neuromonitoring (IONM) software platform that converts raw surgical neurophysiological data into real-time alerts and recommendations. The system acts as a vigilant adjunct to existing IONM platforms, enabling supervising neurophysiologists to monitor multiple cases simultaneously. Built on machine learning algorithms tested on over 1,000 surgeries, AIM™ addresses the shortage of qualified neurophysiology experts in spine surgery, neurosurgery, and ENT procedures.

Product overview

Nervio offers a single unified product: AIM™ (Artificial Intelligence Monitoring), an AI-powered intraoperative neuromonitoring (IONM) solution. AIM™ is the company's core and only product—a software-defined platform that converts raw surgical neurophysiological data into real-time alerts and recommendations, serving as an AI adjunct to standard IONM platforms. The system is designed to address workforce shortages of neurophysiology specialists and reduce burnout and human error among neuromonitoring professionals during surgeries.

Differentiator

Problem solved

Functional benefit

Products and services

• AIM™ (AI Monitoring) AIM™ is the first and only AI-powered intraoperative neuromonitoring (IONM) software platform that converts raw surgical neurophysiological data into real-time alerts and recommendations. Built on machine learning algorithms tested on over 1,000 surgeries, it serves as a vigilant adjunct to existing IONM platforms for spine, neurosurgical, and ENT procedures, and is designed for supervising neurophysiologists, neuromonitoring technologists, hospitals, surgical centers, and IONM service providers.

Quantifiable outcome

• Enables one expert to monitor multiple cases simultaneously without compromising professionalism and care quality
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Global Neurosciences Institute (GNI)coreStrategic or Co-development Partner · 1 December 2022First US clinical trial site for Nervio's AI-based IONM system. Partnership with Prof. Sarkar Atom and Dr. William Castro enabled launch of first US clinical validation study.
• BromediconcoreStrategic or Co-development Partner · 1 November 2022One of the dominant neurophysiology service providers in the US, part of Medsurant Health organization. Collaboration led by William Castro, President of Bromedicon. Key partner for US clinical validation and market access.
• Medsurant HealthcoreStrategic or Co-development Partner · 1 November 2022Leader in IONM and one of the largest and most respected providers of neurophysiological intraoperative monitoring services in the US. CEO Stephen Houff involved in partnership collaboration. Key strategic partner for US market entry.
• Spes Medica & Orgil Medical Equipment Ltd.minorStrategic or Co-development Partner · 1 August 2022Leading consortium of two major players in the IONM ecosystem in Europe and Israel. Strategic investors providing market access and industry expertise in the IONM equipment space.
• Mor Research ApplicationsminorStrategic or Co-development Partner · 1 August 2022Technology Transfer Office of Clalit Health Services, the largest HMO in Israel. Provides access to clinical research infrastructure and Israeli healthcare ecosystem connections.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nervio